Pre-made Brentuximab Vedotin benchmark antibody (Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/D1S166E/Ki-1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Brentuximab Vedotin benchmark antibody (Whole mAb ADC, anti-TNFRSF8 therapeutic antibody, Anti-CD30/D1S166E/Ki-1 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Brentuximab vedotin (INN; trade name Adcetris) is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD3 antigen, a defining marker of Hodgkin lymphoma and ALCL.[2] The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seattle Genetics in the US.[3]
| Products Name (INN Index) | Pre-Made Brentuximab Vedotin Biosimilar, Whole Mab Adc, Anti-Tnfrsf8 Antibody: Anti-CD30/D1S166E/Ki-1 therapeutic antibody Drug Conjugate |
|---|---|
| INN Name | brentuximab vedotin |
| Target | TNFRSF8 |
| Format | Whole mAb ADC |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – kappa |
| VD LC | IgG1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Seattle genetics, Inc. (Bothell WA USA) / Takeda Pharmaceutical?Co. Ltd. (Osaka Japan) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TNFRSF8 |
| Package |
